LAMIVUDINA/ZIDOVUDINA SANDOZ 150mg / 300mg tablets medication leaflet

J05AR01 lamivudine + zidovudine • Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations

The combination of lamivudine and zidovudine is used for the treatment of HIV-1 infection. Both substances are antiretrovirals that inhibit viral replication by interfering with reverse transcriptase.

The medication is taken orally, usually twice daily, as directed by a doctor. It is important to follow the treatment regimen to prevent the development of viral resistance.

Side effects may include nausea, anemia, fatigue, or muscle pain. In rare cases, lactic acidosis, myelosuppression, or severe allergic reactions may occur.

This combination is not recommended for patients with severe renal impairment, severe anemia, or hypersensitivity to any of the components.

General data about LAMIVUDINA/ZIDOVUDINA SANDOZ 150mg / 300mg

Substance: lamivudine + zidovudine

Date of last drug list: 01-05-2018

Commercial code: W64236001

Concentration: 150mg / 300mg

Pharmaceutical form: tablets

Quantity: 60

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: PHARMADOX HEALTHCARE LTD. - MALTA

Holder: SANDOZ S.R.L. - ROMANIA

Number: 10471/2017/01

Shelf life: 3 years

Combinations with other substances